BioSpace News Archive

Cash, cash equivalents and marketable securities totaled $16.0 million as of September 30, 2017, compared to $23.5 million as of December 31, 2016.

Brexanolone achieved the primary endpoint in both trials, a mean reduction from baseline in the Hamilton Rating Scale for Depression total score compared to placebo at 60 hours.

This marks the hospital’s second MRIdian system, furthering their leadership role in the delivery of MR-guided radiation therapy.

Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

The proposal includes the distribution of all shares in Arjo, where each share of series A in Getinge entitles to one share of series A in Arjo and each share of series B in Getinge entitles to one share of series B in Arjo.

Christina will report to CEO Christine Lind and will join Medivir’s executive management team.

Positive Opinion Based on Five Studies Demonstrating Nplate Reduces Rates of Bleeding in Children With Rare Blood Disorder [10-November-2017] THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opini

The studies will be under the supervision of Professor Han-Mo Chiu, Clinical Professor, Department of Internal Medicine of NTU who will be the Principal Investigator for both trials.

Together, Brains On-Line and Charles River are a premier early-stage research and development partner for neuroscience drug discovery.

In other countries, Vertex will begin the country-by-country reimbursement process following Marketing Authorization.